significantMechanism

Multi-lineage KIT D816V clonality mapped in SM with associated hematological neoplasms

Systemic Mastocytosis →

Summary

Sotlar et al. demonstrated that KIT D816V is present across multiple hematopoietic lineages (mast cells, monocytes, eosinophils) in SM-AHN, proving SM is a clonal stem cell disorder rather than a mast cell-restricted disease. This finding has implications for treatment, as stem cell-targeting therapies may be needed for deep remission.

Related genes

KITD816V (c.2468A>T)
The central driver mutation of systemic mastocytosis. Causes constitutive ligand-independent activation of the KIT receptor tyrosine kinase, driving mast cell proliferation, survival, and activation. Arises in early hematopoietic stem/progenitor cells.

More from Systemic Mastocytosis

significantTreatment update

PIONEER 3-year follow-up confirms sustained avapritinib benefit in ISM

significantNew research

Swedish and Danish population-based studies reveal higher SM prevalence than expected

breakthroughTreatment update

Avapritinib FDA-approved for indolent systemic mastocytosis (PIONEER trial)

incrementalTreatment update

Avapritinib molecular responses in advanced SM: 30% achieve D816V undetectable

ID: systemic-mastocytosis-update-7Type: mechanismImpact: significant